Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 19;9(2):28.
doi: 10.3390/ph9020028.

Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future

Caryn E Sorge  1 , Jenny K McDaniel  2 , Ana C Xavier  3
Affiliations
Review

Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future

Caryn E Sorge et al. Pharmaceuticals (Basel). .

Abstract

Pediatric Non-Hodgkin Lymphomas (NHL) are a diverse group of malignancies and as such treatment can vary based on the different biological characteristics of each malignancy. Significant advancements are being made in the treatment and outcomes of this group of malignancies. This is in large part due to novel targeted drug therapies that are being used in combination with traditional chemotherapy. Here, we discuss several new lines of therapy that are being developed or are in current use for pediatric patients with NHL.

Keywords: Non-Hodgkin lymphoma; pediatric; targeted therapies.

PubMed Disclaimer

References

    1. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. Depletion of b cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445. - PubMed
    1. Maloney D.G., Smith B., Rose A. Rituximab: Mechanism of action and resistance. Semin. Oncol. 2002;29:2–9. doi: 10.1053/sonc.2002.30156. - DOI - PubMed
    1. Coiffier B., Haioun C., Ketterer N., Engert A., Tilly H., Ma D., Johnson P., Lister A., Feuring-Buske M., Radford J.A., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood. 1998;92:1927–1932. - PubMed
    1. Czuczman M.S., Grillo-Lopez A.J., White C.A., Saleh M., Gordon L., LoBuglio A.F., Jonas C., Klippenstein D., Dallaire B., Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and chop chemotherapy. J. Clin. Oncol. 1999;17:268–276. - PubMed
    1. Vose J.M., Link B.K., Grossbard M.L., Czuczman M., Grillo-Lopez A., Gilman P., Lowe A., Kunkel L.A., Fisher R.I. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-hodgkin’s lymphoma. J. Clin. Oncol. 2001;19:389–397. doi: 10.1080/10428190500217312. - DOI - PubMed